Vimpat 10 MG/ML solution 200ML
Ended Awarded
- Contract number
- SPE2DB25FZ0RX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,323
Award facts
- Contract value 100% obligated
- $1,322.67 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for VIMPAT 10 mg/mL solution in 200 mL quantities, valued at $1,322.67, with a completion date of September 9, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor for medical procurement, particularly serving military and veteran healthcare systems through the DLA Medical Supply Chain. VIMPAT (lacosamide) is a neurological medication used in seizure management, consistent with the company's extensive portfolio of therapeutic pharmaceuticals ranging from specialty medications to generic drugs. The parent IDC enables AmerisourceBergen to supply pharmaceutical products and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The DLA is planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen among the critical contractors supporting these federal medical supply initiatives.
Quick answers
Who was awarded contract SPE2DB25FZ0RX?
SPE2DB25FZ0RX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FZ0RX worth?
The government has obligated $1,323 on SPE2DB25FZ0RX.
Is contract SPE2DB25FZ0RX an order under another contract?
Yes. SPE2DB25FZ0RX is a delivery order under SPE2DB22D3301, an indefinite delivery contract.
Was contract SPE2DB25FZ0RX competed?
The extent of competition for SPE2DB25FZ0RX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award